Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation

Ann Allergy Asthma Immunol. 2021 Sep;127(3):391-392. doi: 10.1016/j.anai.2021.05.028. Epub 2021 May 31.

Authors

Laurence Bouillet¹, Alexis Bocquet², Aude Belbezier², Isabelle Boccon-Gibod²

Affiliations

¹ Department of Internal Medicine, National Reference Centre for Bradykinin-Mediated Angioedemas (CREAK), Grenoble University Hospital, Grenoble, France. Electronic address: lbouillet@chu-grenoble.fr.
² Department of Internal Medicine, National Reference Centre for Bradykinin-Mediated Angioedemas (CREAK), Grenoble University Hospital, Grenoble, France.

PMID: 34082125
DOI: 10.1016/j.anai.2021.05.028

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Angioedemas, Hereditary / drug therapy*
Angioedemas, Hereditary / genetics
Antibodies, Monoclonal, Humanized / therapeutic use*
Complement C1 Inhibitor Protein / therapeutic use
Factor XII / genetics
Female
Humans
Middle Aged
Mutation
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Complement C1 Inhibitor Protein
lanadelumab
Factor XII